Compositions and methods for classifying thyroid nodule disease
A system for classifying thyroid nodule tissue as malignant or benign is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated to with either malignant or benign thyroid nodule disease. The thyroid classification system provides for sets of “thyroid classifying” target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying thyroid nodule tissue.
1. A method, comprising:
(a) assaying by sequencing, array hybridization or nucleic acid amplification an expression level of each of a first group of transcripts and a second group of transcripts in a test sample from a thyroid of a subject, wherein said test sample is identified as indeterminate by cytological evaluation, wherein said first group of transcripts includes at least two transcripts having at least about 90% sequence homology to at least two sequences selected from SEQ ID No. 1-6, 11-13, 16-248, and said second group of transcripts includes at least two transcripts having at least about 90% sequence homology to at least two sequences selected from SEQ ID No. 7-10, 14, 15, 249-584, and wherein said assaying comprises use of probes selected for said at least two sequences; and
(b) in a programmed computer, comparing said expression level of each of said first group of transcripts and said second group of transcripts with reference expression levels of transcripts corresponding to sequences as set forth in SEQ ID No. 1 to 584 to (1) classify said test sample as malignant for a thyroid condition if there is an increase in an expression level corresponding to said first group of transcripts or a decrease in an expression level corresponding to said second group of transcripts, or (2) classify said test sample as benign for said thyroid condition if there is an increase in said expression level corresponding to said second group of transcripts or a decrease in said expression level corresponding to said first group of transcripts.
2. The method of claim 1 , further comprising (i) when said test sample is classified as malignant, treating said subject by surgical removal of at least a portion of a thyroid tissue, radioactive iodine treatment, or a combination thereof or (ii) when said test sample is classified as benign, monitoring said subject by repeating (a)-(b) on another test sample obtained from said subject at a later time.
3. The method of claim 1 , further comprising performing a cytological analysis, an imaging analysis, a measurement of thyroid hormone levels, or any combination thereof to obtain a result, and combining said result with said expression level to determine a classification of said test sample as malignant or benign for said thyroid condition.
4. The method of claim 1 , further comprising generating a report that designates said test sample as malignant or benign for said thyroid condition.
5. The method of claim 2 , wherein said treating further comprises thyroid hormone suppression therapy, permanent thyroid hormone replacement therapy, or a combination thereof.
6. The method of claim 1 , wherein an increased relative level of expression of one or more transcripts, a decreased relative level of expression of one or more transcripts, or a combination thereof is used to classify said test sample as malignant for said thyroid condition.
7. The method of claim 1 , wherein an increased relative level of expression of one or more transcripts, a decreased relative level of expression of one or more transcripts, or a combination thereof is used to classify said test sample as benign for said thyroid condition.
8. The method of claim 1 , wherein said at least two transcripts comprise at least two sequences having at least about 90% sequence homology to any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
9. The method of claim 1 , wherein said at least two transcripts comprise at least two sequences having at least about 90% sequence homology to any one of SEQ ID NOs: 1, 11, 12, 13, 14, and 15.
10. The method of claim 1 , wherein said assaying comprises determining said expression level by RT-PCR, Northern blotting, ligase chain reaction, or any combination thereof.
11. The method of claim 1 , wherein said test sample is fresh-frozen or fixed.
12. The method of claim 1 , wherein said expression level is measured by pattern recognition.
13. The method of claim 12 , wherein said pattern recognition comprises a linear combination of expression levels of target sequences.
14. The method of claim 12 , wherein said pattern recognition comprises a nonlinear combination of expression levels of target sequences.
15. The method of claim 1 , wherein (b) comprises using said programmed computer to (1) classify said test sample as malignant for said thyroid condition if there is an increase in an expression level corresponding to said first group of transcripts and a decrease in an expression level corresponding to said second group of transcripts, or (2) classify said test sample as benign for said thyroid condition if there is an increase in said expression level corresponding to said second group of transcripts and a decrease in said expression level corresponding to said first group of transcripts.
16. The method of claim 1 , wherein said assaying is by nucleic acid amplification using at least one probe that amplifies a transcript having at least about 90% sequence homology to a sequence as set forth in any one of SEQ ID No. 1 to 584.
17. The method of claim 1 , wherein said first group of transcripts includes a sequence having at least about 90% sequence homology to a sequence as set forth in any one of SEQ ID No. 1-6 and 11-13.
18. The method of claim 1 , wherein said second group of transcripts includes a sequence having at least about 90% sequence homology to a sequence as set forth in any one of SEQ ID No. 7-10 and 14.